Anzeige
Mehr »
Dienstag, 02.09.2025 - Börsentäglich über 12.000 News
Milliardenmarkt Multiple Sklerose: Neue Therapieform könnte alles verändern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 889714 | ISIN: SE0000202624 | Ticker-Symbol: GTN
Frankfurt
02.09.25 | 08:04
18,995 Euro
+1,85 % +0,345
1-Jahres-Chart
GETINGE AB Chart 1 Jahr
5-Tage-Chart
GETINGE AB 5-Tage-Chart
RealtimeGeldBriefZeit
18,61018,81522:33
18,67018,67522:00
PR Newswire
174 Leser
Artikel bewerten:
(1)

Getinge Interim Report April-June 2025: Continuing positive trend with stable organic sales growth in all business areas and regions

GOTHENBURG, Sweden, July 18, 2025 /PRNewswire/ -- "The positive start to 2025 continued in the second quarter, with stable organic growth in order intake and sales, and our margins strengthened despite strong headwinds from tariffs and negative currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 4.1% while order intake rose by 4.4% organically.

Business area Acute Care Therapies continues to be successful in handling the increased demand for ventilators, and the order intake in ECLS consumables remains high. The positive trend for Sterile Transfer in Life Science strengthened during the quarter, while the rationalizations in Getinge's Bio-Processing business are fully underway.

"This means that we will be well positioned for profitable growth in Bio-Processing when demand returns. In Surgical Workflows, Infection Control and Digital Health Solutions delivered significant growth," says Mattias Perjos, President & CEO.

Paragonix, acquired in the autumn of 2024, continues to impress, with another sales record in the quarter. The operations also made a positive contribution to Getinge's EBITA margin, slightly earlier than expected.

Another important milestone for Getinge was the first use of the next generation of endoscopic vessel harvesting (EVH) product, Vasoview Hemopro 3, in clinical procedures in the US.

"The results were positive, and we expect to start deliveries on a larger scale during the third quarter," Perjos tells. "In Life Science, we launched a new washer and in Surgical Workflows we continue to strengthen our offering in consumables, where we have achieved high growth. Surgical Workflows also entered an exciting partnership with Zimmer Biomet that enhances our presence in the rapidly growing ASC segment in the US market."

Adjusted EBITA increased in the quarter, despite close to -270 MSEK in tariffs and negative currency effects compared with last year.

"We were once again successful in adjusting prices, but short term we have been forced to absorb most of the tariff costs. Accordingly, we are also analyzing opportunities to adapt the company's costs and supply chain over time to these new rules of the game. We are well positioned to manage these challenges by leveraging our leading position in key niches that meet long-term increasing healthcare needs," explains Perjos.

In light of the tariff levels noted in the second quarter, Getinge sees no need to change its long-term financial target.

"Given our performance and dialogue with customers, my outlook for the remainder of 2025 is positive, even though geopolitical risk is elevated. I would like to thank all of our customers and employees for their important efforts in creating value for clinical staff and patients," says Perjos.

April- June 2025 in brief

  • Net sales increased organically by 4.1% (8.9) and order intake rose by 4.4% organically (7.8).
  • Adjusted gross profit amounted to SEK 4,183 M (4,151) and the margin was 50.8% (50.0).
  • Adjusted EBITA amounted to SEK 989 M (981) and the margin was 12.0% (11.8).
  • Adjusted earnings per share amounted to SEK 2.25 (2.29).
  • Free cash flow amounted to SEK 510 M (289).

Phone Conference

A conference call will be held on July 18, at 10.00-11.00 a.m. CEST hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.

To participate via teleconference, please register via this link. After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.

During the conference call a presentation will be held. To access the presentation through webcast, please use this link. A recorded version can be accessed here for 3 years.

Contact information:

Lars Mattsson, SVP Enterprise Development
Phone: +46(0)10 335 0043
E-mail: [email protected]

This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on July 18, 2025, at 08.00 CEST.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/getinge/r/getinge-interim-report-april-june-2025--continuing-positive-trend-with-stable-organic-sales-growth-i,c4208711

The following files are available for download:

https://mb.cision.com/Main/942/4208711/3584910.pdf

Getinge - Report Q2 2025

https://mb.cision.com/Public/942/4208711/93123e454355430b.pdf

Press release Getinge Interim Report Q2 2025

SOURCE Getinge

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.